The question of whether swallowing a tablet works as effectively as an injection is important for anyone considering their treatment options
Phase 3 trials showed an average A1C drop of around 1.1% over 24 to 30 weeks
The LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide) studies, which collectively followed thousands of patients for several years, did not report significant increases in fracture rates compared to placebo groups
Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K
Palana, C., Aburumman, A., Kachungunu, C